Rani Therapeutics & Highway to Health

On December 3, 1967, Dr. Christiaan Barnard completed the first human heart transplant. At the time, it seemed incredible—and it is—but today, we hardly bat an eye at a heart transplant because of how rapidly the healthcare and biotech fields are coming out with innovative surgeries, technologies, and therapies.

What does the biotech industry look like today and what are some of the new therapeutic options under development?

On today’s episode of Highway to Health, Host David Kemp speaks with Tilat Imran, CEO of Rani Therapeutics, to discuss the current and future state of the biotech industry and how Rani’s new “injection” pill works and what are its potential applications.

Imran discussed how although biotech developments seem to develop slowly, we are in a golden age. The global biotechnology market is anticipated to grow at a compound annual growth rate (CAGR) of 13.9 percent between 2022 and 2030, according to Grand View Research.

“I want to challenge that perception that things are taking too long…I think we live in a golden age of healthcare and biotech. I think we’ll look back 50, 70 years from now and many of us will be alive because of technologies and innovations that are happening right now. And looking at this time and saying, ‘Wow, the pace of innovation, the rate of change went up so dramatically,’” stated Imran.

Kemp and Imran also discussed…

  1. The challenges Rani Therapeutics anticipates and where they are in their journey
  2. The dissolvable injectable pain-free capsule Rani Therapeutics has developed and current health afflictions it can address
  3. What may be available in 5 to 10 years for treatment of chronic diseases in the biotech market

Imran provided examples of all the applications of the Rani capsule. “There’s so many places you can take this. Cardiometabolic disease, diabetes, as you mentioned. All the immunology, autoimmune diseases because biologics are being used everywhere now. So, psoriasis, rheumatoid arthritis, Crohn’s disease, osteoporosis…eventually, we want to do work in oncology. There’s a real potential there, we think, to use Rani pills with more frequent dosing to perhaps get better efficacy out of the same drugs that are being given more infrequently now.”

Imran is CEO of Rani Therapeutics and has previously worked for VentureHealth, InCube Labs, Venture Web Partners, The Angels’ Forum, and Tilat Imran Consulting. Imran studied Commercial Music and Computer Science at Foothill College as well as Computer Science at the University of California, Santa Cruz. He is a skilled healthcare-focused executive.

Recent Episodes

In the first episode of The Michael Rothman podcast, we address misconceptions about sepsis in healthcare. Although it’s often claimed that sepsis accounts for nearly a third of hospital deaths, many of these deaths are linked to chronic conditions with sepsis as a secondary factor. The frequently cited statistic that delays in treating sepsis increase…

CEO turnover across U.S. hospitals is accelerating. Hospitals and health systems announced 146 CEO changes in 2023—a 42 percent increase over the 103 exits recorded in 2022, according to a Challenger, Gray & Christmas report. As more leaders transition into new roles, the importance of making a good first impression has intensified. The early…

In this episode of Care Anywhere, host Lea Sims sits down with Louis Brownstone, President of WorldWide HealthStaff Solutions, to explore how one of the largest global staffing organizations is giving back to nursing education in meaningful, long-term ways. While known for their direct hire placements across the U.S. and Middle East, WorldWide is also…